DEVELOPING A NOVEL APPROACH TO ALLERGEN IMMUNOTHERAPY


OUR MISSION IS TO PROVIDE LONG-LASTING PEACE OF MIND TO FOOD ALLERGY SUFFERERS

 

Prota Therapeutics, a late clinical-stage biotech company, is dedicated to advancing allergen oral immunotherapies for treating food allergies, particularly addressing the prevalent and potentially life-threatening issue of peanut allergies. The development of our technology stems from over two decades of rigorous research led by Professor Mimi Tang at the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia. Our phase-3 ready lead product, PRT120, specifically targets peanut allergy, underscoring the critical importance of advancing treatments for this serious condition, ultimately aiming to enhance the quality of life for affected patients.

 

Prota’s food allergy treatments are investigational and are not approved for marketing in any region.